FDA Approves Zepbound for Obstructive Sleep Apnea: A Weight Loss Breakthrough
The Food and Drug Administration (FDA) has taken a groundbreaking step by approving Zepbound, a prescription medication developed by Eli Lilly & Co., to treat obstructive sleep apnea (OSA). This decision marks a significant milestone in addressing the health challenges associated with obesity-related sleep disorders. Obstructive sleep apnea is a common condition where individuals experience … Read more
